Navigation Links
Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Date:1/25/2012

ently available therapies, indicate that CMX001 has the potential to improve outcomes for immunosuppressed patients.

CMX001 Study 201 is a randomized, placebo-controlled Phase 2 study of CMX001 as prophylaxis for CMV in hematopoietic cell transplant recipients.  230 subjects were randomized (3:1) to receive CMX001 or placebo in five sequential, dose-escalating cohorts.  Subjects were dosed either once weekly (QW) or twice weekly (BIW) for nine to 11 weeks until post-transplant week 13, with a four-to-eight week follow-up period. 

To date, more than 700 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.  Recently presented data from 183 patients who received CMX001 within a compassionate setting indicated that CMX001 showed no indication of the myelosuppression or nephrotoxicity associated with currently available antiviral therapies.

About Chimerix
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  Utilizing proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. 

In addition to the company's development of its lead candidate, CMX001, for transplant recipients,  CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, with the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised, or a household contact of a contraindicated individual, and thus not candidates to receive a smallpox vaccine (for additional information, please see http://www.bt.cdc.gov/agent/s
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences
2. Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
3. Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
4. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
5. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
6. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
7. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
8. Chimerix to Present at the Citi 2011 Global Health Care Conference
9. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Remedy Informatics, ... healthcare and life sciences research, today announced it ... (GSA) IT Schedule 70 supply contract (GS-35F-367AA, effective ... provide innovative IT solutions to government agencies at ... this contract, Remedy has placed its products and ...
(Date:6/18/2013)... June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a general corporate update in conjunction with ... Tuesday, June 25 at 2:10 p.m. Pacific Time in ... the meeting is as follows: 2:00 p.m. – 2:10 p.m. ... of April 26, 2013) 2:10 p.m. – 3:15 p.m. Corporate ...
(Date:6/17/2013)... , June 17, 2013  Hanger, Inc. (NYSE:  HGR) ... agreement that increases its senior secured facilities to an ... previously.  The new credit agreement includes a $200 million ... facility.  The previous credit agreement was comprised of a ... term loan.  Each new facility matures on June 17, ...
Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3
(Date:6/18/2013)... (PRWEB) June 18, 2013 Exposed Skin Care ... thousands of acne suffers of all ages finally achieve the ... acne treatment products, this new acne clearing system combines the ... and prevent new acne from forming. , After ... believes these products are some of the most effective available ...
(Date:6/18/2013)... 19, 2013 "What if adding one ... could boost your health and well-being? Well, there is ... Sublime Beauty®. "It is called Skin Brushing ." ... became a lost art. Now, people are rediscovering this ... Brushing, and so do certain health conscious people. Sublime ...
(Date:6/18/2013)... PA, June 19, 2013 Recent studies linking ... of bullying-related suicide among young people, led the ... assemble an expert panel to focus on these ... the complex relationship between youth involvement in bullying ... among youth is a significant public health problem, ...
(Date:6/18/2013)... Parker Waichman LLP, a national law ... by dangerous drugs and medical devices, has filed a ... that she was injured by transvaginal mesh ... the U.S. District Court for the Southern District of ... litigation entitled In Re: American Medical Systems, Inc., Pelvic ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
Breaking Medicine News(10 mins):Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Bullying and suicide among youth is a public health problem 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2
... Department of Orthopaedic Surgery at the University of Pittsburgh School of ... Center (UPMC) for Sports Medicine will be installed as the 37th ... Saturday, July 12, 2008, during the Society,s Annual Meeting in Orlando, ... ...
... NASHVILLE, Tenn., July 2 Ambulatory Services of,America, ... Dallas, LLP, its,sixth joint venture to provide outpatient ... joint venture between ASA,s subsidiary, Radiation,Oncology Services of ... Landmark,Radiation Dallas LP. ROSA of North Dallas will ...
... Senate, derailing a critical bipartisan bill that would have ... to physicians who,treat Medicare patients, and made significant improvements ... Last week, Sen. Richard Lugar joined a minority of ... people on Medicare continued,access to their doctors and improved ...
... childbirth as most common reason for hospitalizations, analysis finds ... more than 1.2 million Americans -- roughly equivalent to ... a federal government analysis of hospital admissions and costs ... the most common reason for admission to hospital, and ...
... company with an outstanding track record in the ... technologies, announced availability of the Genomatix Genome Analyzer ... first integrated hardware / software solution for in-depth ... (NGS) devices as provided by Illumina, Roche (454), ...
... simplex out of hiding could bring about a cure, scientists ... Americans are afflicted by breakouts of unsightly cold sores, caused ... finally offering them the possibility of a cure. , Scientists ... herpes simplex 1 slips into dormancy and stays dormant -- ...
Cached Medicine News:Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 2Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 3Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 4Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 3Health News:Next generation data analysis for next generation sequencing data 2Health News:New Hope Against the Cold Sore Virus 2Health News:New Hope Against the Cold Sore Virus 3
... establish the patient reportable range and establish ... Linearity is available in five-vial sets with ... 3700 and 4000; Bayer ADVIA 120; Coulter ... 755; Sysmex R-3000, R-3500, R-1000, RAM-1, XE-2100 ...
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
... red blood cell (nRBC) control for evaluating the ... 755 hematology analyzer in its enumeration of the ... LH 750/LH 755. nRBC-Chex for LH is a ... for LH has a 75-day closed-vial stability and ...
... Sickle-Chex is a positive and negative whole ... of Hemoglobin S in solubility tests and ... SICKLEDEX and other manufacturers' solubility kits. ... squeeze dropper vial. The vial dispenses an ...
Medicine Products: